Author

A. L. Taylor

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Cell Biology· 1 Evolutionary Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Assay:proteomics· 3 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

T. N. Starr· 4 shared D. Corti· 2 shared D. Veesler· 2 shared J. Quispe· 2 shared Y.-J. Park· 2 shared A. Balmeli· 1 shared A. Finigan· 1 shared A. K. Uryga· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBiochemistry

T. N. Starr

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Delineating the functional activity of antibodies with cross-reactivity to SARS-CoV-2, SARS-CoV-1 and related sarbecoviruses

F. Ruiz, W. Foreman, M. Lilly, V. A. Baharani, D. M. Depierreux, V. Chohan, A. L. Taylor, J. Guenthoer, D. Ralph, F. A. Matsen, H. Y. Chu, P. D. Bieniasz, M. Cote, T. N. Starr, J. Overbaugh

This study identifies cross-reactive antibodies against SARS-CoV-2 and related sarbecoviruses that target conserved epitopes and show broad neutralization potential.

bioRxiv · Apr 24, 2024Immunology

Broadly neutralizing antibodies against emerging delta-coronaviruses

M. Rexhepaj, Y.-J. Park, L. Perruzza, D. Asarnow, M. McCallum, K. Culap, C. Saliba, G. Leoni, A. Balmeli, C. Yoshiyama, M. S. Dickinson, J. Quispe, J. T. Brown, M. A. Tortorici, K. R. Sprouse, , D. Veesler

The paper isolates two human monoclonal antibodies that broadly neutralize PDCoV variants and identifies their mechanism of action.

bioRxiv · Mar 27, 2024 · PreprintBiochemistry

Broad receptor tropism and immunogenicity of a clade 3 sarbecovirus

J. Lee, S. Zepeda, Y.-J. Park, A. L. Taylor, J. Quispe, C. Stewart, E. M. Leaf, C. Treichel, D. Corti, N. P. King, T. N. Starr, D. Veesler

This study characterizes the receptor tropism and antigenicity of a clade 3 sarbecovirus, identifying broad ACE2 usage and cross-neutralizing antibodies with implications for vaccine design.

bioRxiv · Sep 12, 2023Biochemistry

Deep mutational scans of XBB.1.5 and BQ.1.1 reveal ongoing epistatic drift during SARS-CoV-2 evolution

A. L. Taylor, T. N. Starr

This study uses deep mutational scans to analyze epistatic effects in SARS-CoV-2 variants XBB.1.5 and BQ.1.1, revealing ongoing epistatic drift in mutation impacts.

bioRxiv · Sep 11, 2023Evolutionary Biology

Primed smooth muscle cells acting as first responder cells in disease

M. D. Worssam, J. Lambert, S. Oc, A. L. Taylor, L. Dobnikar, J. Chappell, J. L. Harman, N. L. Figg, A. Finigan, K. Foote, A. K. Uryga, M. R. Bennett, M. spivakov, H. Jorgensen

This study identifies SCA1+ vascular smooth muscle cells as first responders that drive clonal proliferation in vascular injury and atherosclerosis.

bioRxiv · Oct 19, 2020Cell Biology